Skip to main content
Erschienen in: Tumor Biology 5/2016

27.11.2015 | Original Article

Epithelial–mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin

verfasst von: Jun li Ma, Shan Zeng, Yan Zhang, Gan lu Deng, Hong Shen

Erschienen in: Tumor Biology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Drug resistance is one characteristic of hepatocellular carcinoma (HCC) and can affect the prognosis of patients directly. To explore drug resistance well, we established an oxaliplatin (OXA)-resistant cell line Bel-7402/OXA by exposure to gradually increased concentration of OXA. Some biological characters, such as proliferation, migration, and invasion, were studied. Drug sensitivity and the mechanisms of drug resistance were also investigated. We found that the resistant index of Bel-7402/OXA was 8.3. In comparison with Bel-7402, the percentages of cells in S and G2/M phase were increased. The nature apoptosis rate and drug-after apoptosis rate were all decreased in Bel-7402/OXA, as compared to Bel-7402. Bel-7402/OXA acquired increased migration and invasion ability with epithelial–mesenchymal transition (EMT) phenotype. Knockdown of EMT transcription factor Snail could reverse EMT and sensitized Bel-7402/OXA cells to OXA. EMT was one mechanism of drug resistance and may be a novel target of treatment for drug resistance.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Liccioni A, Reig M, Bruix J. FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive? J Hepatol. 2014;61:164–65.CrossRefPubMed Liccioni A, Reig M, Bruix J. FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive? J Hepatol. 2014;61:164–65.CrossRefPubMed
3.
Zurück zum Zitat Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, et al. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. A systematic review and pooled analysis. Clin Oncol (R Coll Radiol). 2014;26:488–96.CrossRef Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, et al. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. A systematic review and pooled analysis. Clin Oncol (R Coll Radiol). 2014;26:488–96.CrossRef
4.
Zurück zum Zitat Sui H, Zhu L, Deng W, Li Q. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies. Oncol Res Treat. 2014;37:584–9.CrossRefPubMed Sui H, Zhu L, Deng W, Li Q. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies. Oncol Res Treat. 2014;37:584–9.CrossRefPubMed
5.
Zurück zum Zitat Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:5820–8.CrossRefPubMedPubMedCentral Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:5820–8.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Wang H, Zhang G, Zhang H, Zhang F, Zhou B, et al. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/beta-catenin/Snail signaling pathway. Eur J Pharmacol. 2014;723:156–66.CrossRefPubMed Wang H, Zhang G, Zhang H, Zhang F, Zhou B, et al. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/beta-catenin/Snail signaling pathway. Eur J Pharmacol. 2014;723:156–66.CrossRefPubMed
7.
Zurück zum Zitat Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, et al. Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol. 2012;40:1005–10.PubMed Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, et al. Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol. 2012;40:1005–10.PubMed
8.
Zurück zum Zitat Chow AK, Ng L, Lam CS, Wong SK, Wan TM, et al. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. Plos One. 2013;8:e78675.CrossRefPubMedPubMedCentral Chow AK, Ng L, Lam CS, Wong SK, Wan TM, et al. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. Plos One. 2013;8:e78675.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501–8.CrossRefPubMed Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501–8.CrossRefPubMed
10.
Zurück zum Zitat Coriat R, Mir O, Cessot A, Brezault C, Ropert S, et al. Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Invest New Drugs. 2012;30:376–81.CrossRefPubMed Coriat R, Mir O, Cessot A, Brezault C, Ropert S, et al. Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Invest New Drugs. 2012;30:376–81.CrossRefPubMed
11.
Zurück zum Zitat Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, et al. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. Clin Oncol (R Coll Radiol). 2014;26:488–96.CrossRef Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, et al. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. Clin Oncol (R Coll Radiol). 2014;26:488–96.CrossRef
12.
Zurück zum Zitat Qin S, Cheng Y, Liang J, Shen L, Bai Y, et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist. 2014;19:1169–78.CrossRefPubMedPubMedCentral Qin S, Cheng Y, Liang J, Shen L, Bai Y, et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist. 2014;19:1169–78.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Xiu P, Dong X, Dong X, Xu Z, Zhu H, et al. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Sci. 2013;104:375–82.CrossRefPubMed Xiu P, Dong X, Dong X, Xu Z, Zhu H, et al. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Sci. 2013;104:375–82.CrossRefPubMed
14.
Zurück zum Zitat Tong X, Han X, Yu B, Yu M, Jiang G, et al. Role of gap junction intercellular communication in testicular Leydig cell apoptosis induced by oxaliplatin via the mitochondrial pathway. Oncol Rep. 2015;33:207–14.PubMed Tong X, Han X, Yu B, Yu M, Jiang G, et al. Role of gap junction intercellular communication in testicular Leydig cell apoptosis induced by oxaliplatin via the mitochondrial pathway. Oncol Rep. 2015;33:207–14.PubMed
15.
Zurück zum Zitat Wen J, Zheng B, Hu Y, Zhang X, Yang H, et al. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep. 2009;22:65–71.PubMed Wen J, Zheng B, Hu Y, Zhang X, Yang H, et al. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep. 2009;22:65–71.PubMed
16.
Zurück zum Zitat Yang AD, Fan F, Camp ER, van Buren G, Liu W, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006;12(14 Pt 1):4147–53.CrossRefPubMed Yang AD, Fan F, Camp ER, van Buren G, Liu W, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006;12(14 Pt 1):4147–53.CrossRefPubMed
17.
Zurück zum Zitat Grygielewicz P, Dymek B, Bujak A, Gunerka P, Stanczak A, et al. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. Gastric Cancer. 2014. Grygielewicz P, Dymek B, Bujak A, Gunerka P, Stanczak A, et al. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. Gastric Cancer. 2014.
18.
Zurück zum Zitat Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2:e179.CrossRefPubMedPubMedCentral Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2:e179.CrossRefPubMedPubMedCentral
Metadaten
Titel
Epithelial–mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin
verfasst von
Jun li Ma
Shan Zeng
Yan Zhang
Gan lu Deng
Hong Shen
Publikationsdatum
27.11.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4458-z

Weitere Artikel der Ausgabe 5/2016

Tumor Biology 5/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.